TGF-β and Cancer Immunotherapy.

Area of Science:

• Immunology
• Oncology
• Molecular Biology

Background:

• Transforming growth factor beta (TGF-β) is a cytokine secreted by tumor cells, influencing tumor growth and cancer immunity.
• The SMAD signaling pathway, regulated by TGF-β, plays a critical role in tumor metastasis and immune regulation within the tumor microenvironment.

Purpose of the Study:

• To elucidate the multifaceted roles of TGF-β in regulating immune cells and checkpoints within the tumor microenvironment.
• To explore the therapeutic potential of targeting TGF-β in cancer immunotherapy.

Main Methods:

• Review of existing literature on TGF-β signaling in cancer.
• Analysis of TGF-β's impact on various immune cells (T cells, NK cells, macrophages) and immune checkpoints.
• Examination of current and emerging therapeutic strategies involving TGF-β inhibition.

Main Results:

• TGF-β promotes tumor growth and suppresses anti-tumor immunity, notably by inducing regulatory T cells.
• TGF-β influences the expression of immune checkpoint inhibitory receptors on immune cells.
• Emerging therapies combine immune checkpoint inhibitors, anti-TGF-β antibodies, and TGF-β inhibitors for cancer treatment.

Conclusions:

• TGF-β is a key regulator of the tumor immune microenvironment and a significant target for cancer immunotherapy.
• Combination therapies involving TGF-β blockers and other immunotherapeutic approaches, such as CARs, show promise for enhancing anti-tumor responses.